|1.||Russell, Bruce R: 2 articles (10/2013 - 08/2010)|
|2.||Kirk, Ian J: 2 articles (10/2013 - 08/2010)|
|3.||Bastos, M L: 1 article (01/2016)|
|4.||Arbo, M D: 1 article (01/2016)|
|5.||da Silva, D Dias: 1 article (01/2016)|
|6.||Teixeira, J P: 1 article (01/2016)|
|7.||Barbosa, D J: 1 article (01/2016)|
|8.||Silva, R: 1 article (01/2016)|
|9.||Silva, S P: 1 article (01/2016)|
|10.||Carmo, H: 1 article (01/2016)|
04/06/1993 - "The present investigation was performed to study the chronic effects of TFMPP on food intake and weight gain in genetically obese Zucker rats. "
04/06/1993 - "It is concluded that the anorectic and weight gain-lowering effects of TFMPP decrease during long-term treatment in obese Zucker rats."
04/06/1993 - "Effect of chronic treatment with TFMPP, a 5-HT1 receptor agonist, on food intake, weight gain, plasma insulin and neuropeptide mRNA expression in obese Zucker rats."
08/01/1989 - "1-(1-Naphthyl)piperazine produced moderate increases in responding under shock-avoidance schedules, whereas only decreases in responding were seen after mCPP and TFMPP.(ABSTRACT TRUNCATED AT 250 WORDS)"
03/01/1989 - "The 5-HT agonists trifluoromethylphenylpiperazine (TFMPP), chlorophenylpiperazine (mCPP), and 6-chloro-2(1-piperazinyl)pyrazine (MK-212) increased the intensity at which shock was maintained. "
01/01/1990 - "The 5-HT agonists m-trifluoromethylphenylpiperazine (TFMPP), m-chlorophenylpiperazine (mCPP), and 6-chloro-2(l-piperazinyl)pyrazine (MK-212) decreased responding under both the food and shock schedules (0.3-5.6 mg/kg). "
11/01/1985 - "Intramuscular administration of l-5-HTP (0.3-17 mg/kg), MK-212 (0.01-1.0 mg/kg), TFMPP and CPP (0.03-10 mg/kg) produced dose-related decreases in responding under both the food- and shock-presentation schedules. "
11/01/1985 - "The behavioral effects of the serotonin (5-HT) precursor l-5-hydroxytryptophan (l-5-HTP) and the phenylpiperazine 5-HT agonists 6-chloro-2-(1-piperazinyl)pyrazine (MK-212), 1-(m-trifluromethylphenyl) piperazine (TFMPP), 1-(m-chlorophenyl)piperazine (CPP) and 2-(1-piperazinyl)quinoline (quipazine) were compared with those of the putative 5-HT antagonists metergoline, methysergide, cyproheptadine, cinanserin and ketanserin under a multiple 5-min fixed-interval schedule of food or electric shock presentation in squirrel monkeys. "
07/01/1994 - "The results indicate that the TFMPP-induced decrease in the susceptibility to seizures is connected to stimulation of 5-HT2 or of both 5-HT1C and 5-HT2 receptors. "
07/01/1994 - "TFMPP in intraperitoneal (i.p.) doses of 10, 20 and 40 mg/kg increased the convulsive threshold (the amperage necessary to produce the hindleg tonic extensor component of seizures in 50% of animals) by 28, 60, and 85%, respectively. "
11/01/2002 - "When the data from the five rats with the highest seizure frequency in saline were analyzed for the first 6 h after treatment, TFMPP also significantly reduced seizure frequency. "
03/01/2005 - "At a 10 mg/kg dose, BZP/TFMPP increased dialysate DA more than the summed effects of each drug alone, and some rats developed seizures. "
11/01/2002 - "When compared with saline over the entire 72-h observation period, PB and fluoxetine treatment, but not TFMPP, reduced the spontaneous-seizure rate. "
06/01/1992 - "TFMPP, an agonist at 5-HT1B and 5-HT1C receptors, significantly facilitated lordosis in 5,7-DHT-treated and non-treated rats. "
07/01/1993 - "However, rats pretreated with TFMPP and infused with 8-OH-DPAT 1 hr later, did show a transient suppression of lordosis quality. "
09/07/1998 - "Rats receiving 8-OH-DPAT and 1000 or 2000 ng quipazine or TFMPP were protected from the lordosis-inhibiting effects of 8-OH-DPAT, alone. "
09/07/1998 - "Attenuation of the lordosis-inhibiting effects of 8-OH-DPAT by TFMPP and quipazine."
07/01/1993 - "The nonselective 5-HT agonist, 1-(m-trifluoromethyl) piperazine [TFMPP (2000 ng)], did not reduce lordosis behavior. "
01/01/2016 - "This work aimed to investigate the cytotoxicity of N-benzylpiperazine, 1-(3-trifluoromethylphenyl)piperazine, 1-(4-methoxyphenyl)piperazine and 1-(3,4-methylenedioxybenzyl)piperazine in the differentiated human neuroblastoma SH-SY5Y cell line. "
09/01/1996 - "The ability of phenylpiperazines: 4-phenyl-piperazine (PP), 1-carboxamidino-4-phenyl-piperazine (CAPP), [4-(3-chlorophenyl)-piperazine (mCPP), 4-(3-trifluoro methyl phenyl)-piperazine (TFMPP), and (1,1-dimethyl-4-phenyl)-piperazinium hydrochloride (DMPP) and chlorophenyl hydroxypiperidine [CP(OH)P], to inhibit MIBG uptake by neuroblastoma cells was determined by incubation with [125I]MIBG (0.1 microM) for 2 h in the presence of varying concentrations (10(-8)-10(-3) M) of ligand. "
|1.||Serotonin (5 Hydroxytryptamine)
|3.||Serotonin Receptor Agonists (Serotonin Receptor Agonist)
|10.||Serotonin 5-HT2 Receptor Agonists